Results 241 to 250 of about 326,443 (336)

Trastuzumab Deruxtecan in Previously Treated HER2-Low Metastatic Breast Cancer: Real-World Multicentric Study in the Portuguese Population [PDF]

Luísa Soares‐Miranda, Maria João Sousa, Miguel Martins Braga, Marisa Couto, Isabel Vieira Fernandes, Flavio Berriel Abreu, Inês Eiriz, Catarina Lopes Fernandes, Andréa Marques, Mariângela Esther Alencar Marques, Raquel Romão, Fernando Ribeiro Gonçalves, Joana Simões, António Araújo   +13 more
openalex   +1 more source

Impact of organic pollutants on phenotype and gene expression in human breast cancer cells

Journal of Applied Toxicology, EarlyView.
ABSTRACT Human exposure to industrial chemical compounds is widespread and, although often beneficial, prolonged contact may contribute to disease development, including cancer. While many studies have shown organic pollutants (OP) are cytotoxic, few have explored how long‐term exposure alters cell phenotype.
Camila Confortin, Heloisa Amancio, Jessica Zablocki da Luz, Aliciane de Almeida Roque, Tugstênio Lima de Souza, José Eduardo Vargas, Ciro Alberto de Oliveira Ribeiro, Francisco Filipak Neto   +7 more
wiley   +1 more source

Assessment of the Role of Neutrophil-Lymphocyte Ratio as a Prognostic Biomarker in Breast Cancer Patients: A Cross-sectional Study. [PDF]

Cancer Diagn Progn
Takada K, Kashiwagi S, Nishikawa M, Watanabe C, Tauchi Y, Ogisawa K, Shibutani M, Kinoshita H, Morisaki T.   +8 more
europepmc   +1 more source

HER2 heterogeneity

The Breast, 2021
openaire   +2 more sources

Tumor Heterogeneity in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Gastric Cancer Assessed by CT Texture Analysis: Association with Survival after Trastuzumab Treatment

, 2016
Sung Hyun Yoon, Young Hoon Kim, Yoon Jin Lee, Jihoon Park, Jin Won Kim, Hye Seung Lee, Bohyoung Kim   +6 more
openalex   +2 more sources

Population Pharmacokinetics Analysis of Talazoparib and Enzalutamide Combination Therapy for Patients With Metastatic Castration‐Resistant Prostate Cancer

The Journal of Clinical Pharmacology, EarlyView.
Abstract The poly(ADP‐ribose) polymerase inhibitor talazoparib, combined with the androgen receptor inhibitor enzalutamide is approved for patients with homologous recombination repair (HRR) gene‐mutated metastatic castration‐resistant prostate cancer (mCRPC) in the US and with mCRPC in whom chemotherapy is not clinically indicated in Europe.
Mark Hadigol, Jason H. Williams, Haihong Shi, Derek Z. Yang, Justin Hoffman, Diane D. Wang   +5 more
wiley   +1 more source

Anti-HER2 treatment in everyday practice: how we treat older women with breast cancer differently. [PDF]

Breast Cancer Res Treat
Hjorth S, Vandraas KF, Trewin-Nybråten CB, Botteri E, Ursin G, Andreassen BK, Støer NC.   +6 more
europepmc   +1 more source

Integrative Genomics Reveals Causal Pleiotropy and Therapeutic Opportunities at the Interface of Acute Pancreatitis and Infection

Journal of Hepato-Biliary-Pancreatic Sciences, EarlyView.
ABSTRACT Background Understanding the genetic links between acute pancreatitis (AP) and its infectious comorbidities is crucial for prognosis and therapy, yet remains underexplored. Methods We conducted a comprehensive post‐GWAS analysis using large‐scale summary statistics for AP and 16 infectious diseases. To pinpoint pleiotropic genes, we integrated
Bo Zou, Hao Jiang, Jingsheng Ruan, Daifeng Yang, Xing Chen, Shanshan Cai, Xinglin Yi   +6 more
wiley   +1 more source

Redefining HER2 in Breast Cancer: From Conventional Positivity to Low and Ultralow in the New Era of Antibody-Drug Conjugates. [PDF]

Cancer Res Treat
Koh J, Im SA.
europepmc   +1 more source

Artificial intelligence strategies for predicting kinase inhibitor resistance: A comprehensive review of methods, challenges, and future perspectives

Journal of Intelligent Medicine, EarlyView.
Abstract Kinase inhibitors are essential in targeted cancer therapy, yet resistance often emerges through secondary mutations, activation of compensatory signaling pathways, or drug‐efflux mechanisms. Artificial intelligence (AI) provides a workflow‐based strategy rather than a list of unrelated tools for predicting and addressing kinase‐inhibitor ...
Faris Hassan, Mohanad Ali Deifallah, Alaa Zaghloul, Rania Elgohary   +3 more
wiley   +1 more source